

Correction to: AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)

This is a correction to: Koung Jin Suh, Min-Hee Ryu, Dae Young Zang, Woo Kyun Bae, Hye Seung Lee, Hyeon Jeong Oh, Minsu Kang, Ji-Won Kim, Bum Jun Kim, Peter G S Mortimer, Hee Jung Kim, Keun-Wook Lee, AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20), *The Oncologist*, Volume 28, Issue 9, September 2023, Pages e823–e834, <https://doi.org/10.1093/oncolo/oyad059>

In the originally published version of this manuscript, the ‘Background’ section of the abstract erroneously included the following sentence:

“Although the combination of AZD8186 and paclitaxel was well tolerated, limited clinical efficacy was observed in advanced gastric cancer with PTEN loss.”

The abstract has been corrected online and the Background section now reads as follows:

“Loss of PTEN function leads to increased PI3K β signaling. AZD8186, a selective PI3K β/δ inhibitor, has shown anti-tumor activity in PTEN-deficient preclinical models. This phase 1b/2 study was conducted to determine the safety and efficacy of AZD8186 and paclitaxel combination in patients with metastatic or recurrent gastric cancer (MRGC).”